clinical trial · NCT07307768
Ketamine Biomarker Validation
Soterix Medical·phase1·not yet recruiting·n = 20
Treatment Resistant Depression (TRD)Ketamine (0.25 mg/kg)Ketamine (0.5 mg/kg)Ketamine (0.75 mg/kg)
brief summary
We will be developing an EEG-based biomarker for the effects of ketamine infusion in patients with Depression. We will be analyzing the effects of ketamine infusion on Depression symptoms and EEG signals.
started
Dec 20, 2025
primary completion
Dec 1, 2027
completion
Mar 1, 2028
last updated
Dec 29, 2025
detailed description
This trial is a biomarker development study. We will be examining the effects of various doses of ketamine infusion on depressive symptoms and EEG signals in patients with unipolar depression.
official title
EEG Biomarker Development for Ketamine Administration
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol